Literature DB >> 9809947

Optimal coronary balloon angioplasty with provisional stenting versus primary stent (OCBAS): immediate and long-term follow-up results.

A Rodríguez1, F Ayala, V Bernardi, O Santaera, E Marchand, C Pardiñas, C Mauvecin, D Vogel, L C Harrell, I F Palacios.   

Abstract

OBJECTIVE: This study sought to compare two strategies of revascularization in patients obtaining a good immediate angiographic result after percutaneous transluminal coronary angioplasty (PTCA): elective stenting versus optimal PTCA. A good immediate angiographic result with provisional stenting was considered to occur only if early loss in minimal luminal diameter (MLD) was documented at 30 min post-PTCA angiography.
BACKGROUND: Coronary stenting reduces restenosis in lesions exhibiting early deterioration (>0.3 mm) in MLD within the first 24 hours (early loss) after successful PTCA. Lesions with no early loss after PTCA have a low restenosis rate.
METHODS: To compare angiographic restenosis and target vessel revascularization (TVR) of lesions treated with coronary stenting versus those treated with optimal PTCA, 116 patients were randomized to stent (n=57) or to optimal PTCA (n=59). After randomization in the PTCA group, 13.5% of the patients crossed over to stent due to early loss (provisional stenting).
RESULTS: Baseline demographic and angiographic characteristics were similar in both groups of patients. At 7.6 months, 96.6% of the entire population had a follow-up angiographic study: 98.2% in the stent and 94.9% in the PTCA group. Immediate and follow-up angiographic data showed that acute gain was significantly higher in the stent than in the PTCA group (1.95 vs. 1.5 mm; p < 0.03). However, late loss was significantly higher in the stent than the PTCA group (0.63+/-0.59 vs. 0.26+/-0.44, respectively; p=0.01). Hence, net gain with both techniques was similar (1.32< or =0.3 vs. 1.24+/-0.29 mm for the stent and the PTCA groups, respectively; p=NS). Angiographic restenosis rate at follow-up (19.2% in stent vs. 16.4% in PTCA; p=NS) and TVR (17.5% in stent vs. 13.5% in PTCA; p=NS) were similar. Furthermore, event-free survival was 80.8% in the stent versus 83.1% in the PTCA group (p=NS). Overall costs (hospital and follow-up) were US $591,740 in the stent versus US $398,480 in the PTCA group (p < 0.02).
CONCLUSIONS: The strategy of PTCA with delay angiogram and provisional stent if early loss occurs had similar restenosis rate and TVR, but lower cost than primary stenting after PTCA.

Entities:  

Mesh:

Year:  1998        PMID: 9809947     DOI: 10.1016/s0735-1097(98)00388-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

1.  Are "treatment" bare metal stents superior to "control" bare metal stents? A meta-analytic approach.

Authors:  David M Kent; Thomas A Trikalinos
Journal:  Am Heart J       Date:  2008-01-18       Impact factor: 4.749

Review 2.  Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region.

Authors:  Federico Augustovski; Cynthia Iglesias; Andrea Manca; Michael Drummond; Adolfo Rubinstein; Sebastián García Martí
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Coronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal LAD stenosis: results from the ERACI II study.

Authors:  A Rodriguez; M Rodríguez Alemparte; J Baldi; J Navia; A Delacasa; D Vogel; R Oliveri; C Fernández Pereira; V Bernardi; W O'Neill; I F Palacios
Journal:  Heart       Date:  2003-02       Impact factor: 5.994

4.  Reappraisal Value of a Modified Rotational Atherectomy Technique in Contemporary Coronary Angioplasty Era.

Authors:  Haojian Dong; Daisuke Hachinohe; Zhiqiang Nie; Yoshifumi Kashima; Jianfang Luo; Takuya Haraguchi; Hidemasa Shitan; Tomohiko Watanabe; Yutaka Tadano; Umihiko Kaneko; Takuro Sugie; Ken Kobayashi; Daitaro Kanno; Morio Enomoto; Katsuhiko Sato; Tsutomu Fujita
Journal:  J Interv Cardiol       Date:  2020-01-23       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.